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Abstract
Background: Biologic medications have dramatically enhanced the treatment of many chronic paediatric
inflammatory conditions. Their high cost is a factor that prohibits their broader use. Cheaper generic versions, or
biosimilars, are increasingly being used. Healthcare services are switching some patients over to biosimilars for
economic reasons, known as ‘non-medical switching’. Some patients unsuccessfully switch due to perceived
decreases in efficacy or non-specific drug effects. The implications of failed switching include exhaustion of
therapeutic options, unnecessary exposure to other medications, increased healthcare utilisation, worse patient
outcomes and higher overall healthcare costs. Patient perceptions almost certainly play a role in these ‘failed
switches’.
Methods: A thematic analysis was performed to better understand patient and parent perceptions on non-medical
biosimilar switching. The study was conducted in accordance with the Consolidated Criteria for Reporting
Qualitative Research recommendations. Patients with juvenile idiopathic arthritis currently taking adalimumab were
included.
Results: Nine families were interviewed just prior to a hospital trust-wide non-medical switch to an adalimumab
biosimilar. Several common themes were identified. The most frequent concerns were regarding practical aspects
of the switch including the medication administration device type; the colour of the medication and administration
device; and whether the injections would sting more. The relative safety and efficacy of the biosimilar was raised
although most families felt that there would be no significant difference. Anxieties about the switch were largely
placated by reassurances from the medical team.
Conclusions: We derived recommendations based on existing adult literature and the observations from our study
to optimise the benefits from non-medical biosimilar switching.
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Background
Biologic medications, including monoclonal antibodies,
are medications derived from living organisms. These
medications, including adalimumab, have dramatically
improved outcomes of chronic inflammatory conditions
including refractory juvenile idiopathic arthritis (JIA) [1,
2] and JIA associated uveitis [3, 4].
Biologics are expensive and their cost is a factor that
prohibits their broader use. Many index biologics (bio-
originators) are still subject to copyright patents, con-
tributing to their high cost. However, for several bio-
logics, generic versions (biosimilars) are becoming
available. Unlike conventional medications, biosimilars
are not considered completely equivalent to their bio-
originator as they are large and complex molecules that
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are very sensitive to any slight change in the manufac-
turing process [5].
Biosimilar developers must demonstrate that their bio-
similar is highly similar to the bio-originator (notwith-
standing normal variability inherent to all biologics) and
that there are no clinically meaningful differences re-
garding quality, safety and efficacy [6, 7]. Regulating
bodies, including the European Medicines Agency, and
rheumatology groups have encouraged a Bayesian ap-
proach to the development of biosimilars in order to ab-
breviate licencing pathways, help lower costs and
increase access to these medications [8–10]. Data for
one indication may be extrapolated to others (assuming
the same mechanism of action is used), again easing the
statistical threshold and abbreviating the approval
process [11, 12].
Theoretical concerns when switching to biosimilars in-
clude a loss of efficacy, changes in immunogenicity (in-
cluding the development of anti-drug antibodies) and
differences in the safety profile compared with the bio-
originator [13]. Despite these apprehensions, outcomes
from blinded, randomized, controlled trials in adults
have been reassuring [14]. While this is the case, large
scale paediatric trials are lacking. Nonetheless, health-
care services are tending towards switching patients to
biosimilars for economic reasons, known as ‘non-med-
ical switching’ [13].
Experience among adults suggests that the uptake of
biosimilars in open label environments is hindered when
compared to blinded trials. These ‘failed switches’ are
usually attributed to subjective reports of perceived de-
crease in efficacy or non-specific drug effects [15–17].
These are thought to largely be due to the nocebo effect;
noxious reactions to therapeutic interventions that occur
because of negative expectations of the patient [18].
Emerging paediatric data, while scarce, suggests that
some children also unsuccessfully switch [19]. The im-
plications of failed switching could potentially include
exhaustion of therapeutic options, unnecessary exposure
to other medications, increased healthcare utilisation,
worse patient outcomes and higher overall healthcare
costs.
It is hypothesised that patient perceptions strongly in-
fluence failed biosimilar switching [20].
Methods
This study aims to develop an understanding of the per-
ceptions of paediatric patients and their parents with re-
gard to biosimilar switching. A thematic analysis was
performed. Patients with a diagnosis of JIA, under the
age of 18 years, on adalimumab (a fortnightly subcutane-
ous injection) were included. All families were English
speaking and literate. They were recruited from paediat-
ric rheumatology outpatient clinics at the Bristol
Children’s Hospital and Bristol Eye Hospital, tertiary
hospitals in the United Kingdom, over a two-week
period in December 2018. The study was performed
prior to a trust-wide mandatory change from the adali-
mumab bio-originator to a biosimilar on guidance from
the National Health Service (NHS).
Patients were invited to participate either by telephone
(5 families) or at the time of clinical appointments (4
families). Convenience sampling was predominantly used
with supplementary purposive sampling (aiming to in-
clude a range of patients representative of the typical
distribution of age, gender and disease severity). Inter-
views were conducted in a private setting at the out-
patient department on the same day as scheduled
appointments if possible.
Two researchers with experience in qualitative re-
search methods, but without expertise in paediatric
rheumatology or biologic medications (HL and JL)
ran the patient led, semi-structured interviews. They
had not previously met the families. Participants
understood the purpose of the study and that the in-
terviewers were not part of the treating team, nor
experts in paediatric rheumatology or biologics. Indi-
vidual families were interviewed on a single occasion
and had no further active participation in the study
following the interviews. Patients were interviewed
together with their parent(s). Questions were di-
rected to all participants and specifically to the pa-
tient if they did not volunteer an answer. Prompting
questions were used if required (Additional file 1).
Families were provided a copy of a plain language
summary outlining the process of transition to the
biosimilar (designed by the trust pharmacy and
paediatric rheumatology team) on the day of the in-
terviews (Additional file 2).
Interviews were audiotaped and transcribed verbatim.
Field notes were also taken during the interviews. Names
and identifying features were removed from the tran-
scripts for anonymity.
An inductive approach was taken; identifying and
developing themes from the data [21, 22]. Coding
and analysis were conducted by HL and JL using a
qualitative analysis computer program (NVivo 12.2.0,
QSR International). WR separately coded and ana-
lysed the data using the same program. Analyses
were compared and integrated to create unifying
themes.
Informed, written consent was obtained at the time
of recruitment. The study was prospectively approved
by the University Hospitals Bristol Questionnaire,
Interview & Survey Group. The study was conducted
and written in accordance with the Consolidated Cri-
teria for Reporting Qualitative Research (COREQ)
recommendations [23].
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Results
Of 10 families invited to participate, 9 consented and
completed the interviews (1 declined due to time con-
straints). Eight interviews were conducted with the child
and at least 1 parent contributing, while 1 interview was
conducted with a patient’s parents only. All patients had
a diagnosis of JIA with associated uveitis. Patient demo-
graphics are detailed in Table 1.
Interviews lasted between 6 and 51 min (mean 17). All
patients and parents involved made significant contribu-
tions to the interview answers. Most families raised
some concerns but had an overall positive or apathetic
view on the switch. One family was strongly dissatisfied
about the non-optional change.
The study identified five main themes concerning pa-
tients’ and families’ perceptions of the switch to a biosi-
milar medication; ‘drug administration, ‘concerns’,
‘benefits’, ‘equivalence’, and ‘trust in treating clinicians’.
Some themes contained clear associated sub-themes
outlined in the thematic schema (Fig. 1).
Drug administration
Issues surrounding practicalities of drug administration
were important to most respondents. These issues reso-
nated with the patients more than other issues which
their parents were more concerned about.
Patients were anxious about having access to the same
medication administration device (the bio-originator is avail-
able as either a prefilled syringe or prefilled auto-injecting
pen) and the potential of having to use an unfamiliar device.
“I wasn't sure whether there's going to be an option of
prefilled syringe and pen device … we are using a
prefilled syringe … she said she would like to stick with
that.” (parent)
Past versions of the adalimumab bio-originator
contained a citrate preservative which contributed to
stinging as the medication is injected. Several pa-
tients recall what this felt like and those that have
never been on a stingy preparation were aware of its
existence. Whether the new medication would sting
was a prime concern, although some patients were
able to balance a possible worse outcome on an in-
dividual level against a perceived benefit for society.
“Your concerns as well have been about ‘just tell me
it's not going to hurt anymore’ or … about whether it's
stingy or not.” (parent to patient)
“How would you feel about taking it if it did hurt?
(interviewer) “I think it probably be good for society so
I guess I would probably do it.” (patient)
The colour of a biosimilar medication, administration
device and its packaging was a major concern for most
families. Several families specified concerns about the
colour yellow (no other colours were specified), most at-
tributing this to their previous experience with
methotrexate.
“ … if it is yellow, he's not going to go near it.” (parent)
Table 1 Patient demographic details




Ocular complications Active joint count at
time of review
Uveitis activity at
time of review *
6 F 37 24 Nil 0 Right 0
Left 0
8 F 72 13 Nil 0 Right 2+
Left 2+




11 F 82 27 Nil 1 Right 0.5+
Left 0.5+
12 M 43 25 Cataract 0 Right 0.5+
Left 0.5+
12 F 127 80 Posterior synechiae 0 Right 0
Left 0




15 F 172 21 Nil 0 Right 0.5+
Left 0.5+
17 F 190 59 Nil 0 Right 0.5+
Left 0.5+
*anterior chamber cell grading as per standardization of uveitis nomenclature (SUN) criteria [24]
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“ [if] it is yellow and he can see it is yellow then that
will make him gag because it is a psychological thing.”
(parent)
Concerns
Within the theme of ‘concerns’, anxiety about side effects
was frequently expressed. There was anxiety about switching
from the known to the unknown. For other families, pro-
vided there were no new side effects, they didn’t have any sig-
nificant concerns about switching to a biosimilar medication.
“It's not ideal because you know that something works
and it really is just to know that it's not going to have
the side effects … .” (parent)
“We understand it, as long as he doesn't have any side
effects detrimental to him.” (parent)
Several families were concerned about what would happen
if there were problems with the switch and whether it would
be possible to switch back in the event of a poor outcome.
“If we swap and it is worse, and it doesn't do anything,
what happens then? Are we then stuck effectively with
… the cheaper product?” (parent)
Some were concerned about the logistics of switching
to a biosimilar and whether the home delivery process
would be disrupted, especially given the need to store
these medications in a refrigerator.
“My main concern is that the smooth transition goes
through to [delivery service provider] because they are
not always accurate with the delivery time.” (parent)
There was some uncertainty about whether a biosimi-
lar would be as effective as the bio-originator. Several
patients referred to the fact that as it is cheaper, it may
be inferior. However, many acknowledged that although
this might be a perception, when they explored this
thinking they could rationalise that just because a prod-
uct is cheaper it does not equate to inferiority.
“A lot of people say if it is cheaper then it is not as
good as the most expensive one.” (parent)
“Just because it is cheaper doesn't mean that it is
inferior.” (parent)
Two families suggested switching adult patients prior
to paediatric patients to help mitigate some of these
concerns.
“If you want to change, change the adults but don't
change the children” (parent)
Benefits
Almost all respondents identified cost savings as a bene-
fit of switching to a biosimilar (of note, this was men-
tioned in the pharmacy letter and prompting questions).
“I think it is actually probably really good because I do
not want the NHS to like not work so I think it is
really good that we are going to a cheaper version.”
(patient)
Others identified benefits including greater accessibil-
ity to the drug. Increased access felt important for some
who remember the challenges of getting biological medi-
cation for their child and the impact that doing so had
on their lives. Some families highlighted that cost savings
could mean that resources could be used elsewhere.
“Now that there is somebody else out there they might
not have to fight to get the drug that their kids deserve.
It is good.” (parent)
Fig. 1 Thematic schema
Renton et al. Pediatric Rheumatology           (2019) 17:67 Page 4 of 7
Many patients were theoretically willing to accept the
risk of possible side-effects for the good of other pa-
tients. Patients felt that research data would be another
by-product of the switch and were generally positive
about contributing towards this.
“The competition, you have got more opportunities for
people to … explore and push the boundaries a bit
more in terms of research.” (parent)
Equivalence
Although there were anxieties about a biosimilar
medication being inferior, a significant majority of
respondents expressed that they thought the biosimi-
lar medication would probably be similarly safe and
effective.
“For me, it is the same drug but by a different supplier
so it doesn't really make any difference so I do not
mind at all.” (parent)
Even respondents who had significant anxieties about
inferiority also simultaneously acknowledged there may
be no difference in efficacy. This uncertainty was a rela-
tively universal finding.
“ … as long as it works as well and I guess until we
have tried it, we won't feel reassured about that”
(parent)
Trust in clinical staff
For many respondents, their anxieties and concerns were
mitigated by their faith in their medical team.
“They wouldn't let you have something that's not going
to work.” (parent)
Even families who were very unhappy about the
switch did not blame the medical team and felt that
the decision was out of the hands of clinical staff.
Frustration regarding the forced switch was an un-
common finding and was generally directed towards
the pharmacy, the hospital trust administrators and
the NHS.
Most patients had informally heard about the up-
coming switch through their treating team, disease
support groups or social media. Feedback on the hos-
pital trust pharmacy letter was generally very positive
although several patients suggested that a phone call
or face to face notification by a familiar member of
the treating team may be more effective in the first
instance.
Discussion
To our knowledge this is the first study exploring percep-
tions on switching to biosimilar medications among paedi-
atric patients and their parents. Achieving data saturation
was not a prospective target although clear thematic pat-
terns emerged. While there were minor differences in the
specific coding nomenclature and category structure, the
two separate analyses identified very similar themes des-
pite separate areas of expertise among the analysts.
The researchers anticipated that the major concerns
would be regarding the safety and efficacy of these new
mediations. While these issues arose, the overall senti-
ment was that things would probably be fine and most
families were understanding. Patients’ uncertainties ap-
peared to be placated by their trust in the treating team.
Altruism was a prominent finding with most families
happy to accept the uncertainties of switching for the
greater good of the healthcare system.
The much more prevalent concerns had little to do
with the actual medication. Patients in particular were
most worried about the type of medication administra-
tion device, the presence or absence of a stinging preser-
vative and the colour of the medication and packaging.
Views were strongly shaped by previous experiences; this
was particularly apparent with concerns about the colour
of the new product. By the nature of these patients being
on adalimumab they will all have used methotrexate (a
yellow liquid often with prominent yellow branding and
administration devices) in the past or as part of their
current treatment regimen. Many families who raised this
concern explicitly referred to their previous experience
with methotrexate, its associated side-effects and the psy-
chological sequelae from this.
‘Failed switches’ are not uncommon among adults
undergoing non-medical monoclonal antibody biosimilar
switching with the nocebo factor playing a significant role
[20]. Previous experience and expectation significantly
affect noxious symptoms attributable to the nocebo affect
[25]. Effective communication strategies have been identi-
fied as vital in minimizing this phenomenon among adult
patients [26, 27]. The themes identified in our study may
assist with proactively addressing patient expectations
during medication counselling and patient education pro-
grams in order to minimise the incidence of failed switch-
ing and contribute to an improved patient experience.
It’s known that clinicians often disagree with non-
medical switching and feel that patients should be given a
choice [28]. Nonetheless, it is important to portray a posi-
tive message despite any clinician opinions and biases. We
have outlined recommendations on the basis of existing
adult literature and the observations from this study
(Table 2).
This study is not without limitations. Participants’
responses would be influenced by multiple local
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factors, through both informal (discussions with the
treating team, local media, social media, support
groups) and formal (pharmacy letter) means. Partici-
pant bias may have contributed to the positive out-
look. Purposive selection is subject to selection bias
although this was partially offset by the use of sup-
plementary random sampling for the majority of pa-
tients. The data is also limited to a specific
medication used among a single disease at one
centre. Despite these factors we believe that the
findings are generalisable to other healthcare settings
and other chronic medical conditions treated with
biologics and therapeutic proteins.
Conclusions
With significant financial strain across many healthcare
settings, non-medical biosimilar switching is likely to be
an increasingly frequent occurrence. We hope that the
findings and recommendations from this study may help
clinicians assist their patients through this process.
Additional files
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